Metsera, Inc. operates as a clinical-stage biopharmaceutical company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity and cardiometabolic diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. Metsera, Inc. was formerly known as PHP Newco 1, Inc. The company was incorporated in 2022 and is based in New York, New York. As of November 13, 2025, Metsera, Inc. operates as a subsidiary of Pfizer Inc.
Metrics to compare | MTSR | Peers Peers - average of corresponding metrics from companies closely matching MTSR: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMTSRPeersSector |
|---|---|---|---|---|
P/E Ratio | −23.6x | 0.0x | −0.6x | |
PEG Ratio | −0.37 | 0.00 | 0.00 | |
Price/Book | 22.0x | 0.0x | 2.6x | |
Price / LTM Sales | - | 0.0x | 3.4x | |
Upside (Analyst Target) | −19.2% | 0.0% | 41.1% | |
Fair Value Upside | Unlock | 0.0% | 5.3% | Unlock |